DK1351707T3 - Fremgangsmåder til behandling af autoimmunsygdomme hos et individ og in vitro-diagnostiske analyser - Google Patents
Fremgangsmåder til behandling af autoimmunsygdomme hos et individ og in vitro-diagnostiske analyserInfo
- Publication number
- DK1351707T3 DK1351707T3 DK02714705.7T DK02714705T DK1351707T3 DK 1351707 T3 DK1351707 T3 DK 1351707T3 DK 02714705 T DK02714705 T DK 02714705T DK 1351707 T3 DK1351707 T3 DK 1351707T3
- Authority
- DK
- Denmark
- Prior art keywords
- individual
- treatment
- methods
- autoimmune diseases
- diagnostic assays
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26054101P | 2001-01-09 | 2001-01-09 | |
PCT/US2002/000343 WO2002067760A2 (en) | 2001-01-09 | 2002-01-08 | Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1351707T3 true DK1351707T3 (da) | 2011-07-11 |
Family
ID=22989575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02714705.7T DK1351707T3 (da) | 2001-01-09 | 2002-01-08 | Fremgangsmåder til behandling af autoimmunsygdomme hos et individ og in vitro-diagnostiske analyser |
Country Status (15)
Country | Link |
---|---|
US (3) | US7544357B2 (da) |
EP (2) | EP1351707B9 (da) |
JP (2) | JP4394350B2 (da) |
KR (1) | KR100951409B1 (da) |
CN (2) | CN101612402A (da) |
AT (1) | ATE502648T1 (da) |
AU (1) | AU2002246955B2 (da) |
BR (1) | BR0206364A (da) |
CA (1) | CA2433806C (da) |
DE (1) | DE60239522D1 (da) |
DK (1) | DK1351707T3 (da) |
ES (1) | ES2363761T3 (da) |
HK (1) | HK1061353A1 (da) |
MX (1) | MXPA03006100A (da) |
WO (1) | WO2002067760A2 (da) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1351707B9 (en) * | 2001-01-09 | 2012-01-25 | Baylor Research Institute | Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
US20070148129A1 (en) * | 2003-12-24 | 2007-06-28 | The Walter And Eliza Hall Instiute Of Medical Research | Therapeutic agents and uses therefor |
PT1781705E (pt) | 2004-06-21 | 2014-12-23 | Medarex Llc | Anticorpos contra recetor i do interferão alfa e as suas utilizações |
CA2574150C (en) * | 2004-07-19 | 2018-02-27 | The Johns Hopkins University | Flt3 inhibitors for immune suppression |
NZ554065A (en) * | 2004-10-07 | 2010-12-24 | Univ Zuerich | Use of an anti-interferon-alpha antibody for prevention and treatment of psoriasis |
US7888481B2 (en) * | 2005-02-10 | 2011-02-15 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
BRPI0607490A2 (pt) | 2005-02-10 | 2009-09-08 | Baylor Res Inst | anticorpos monoclonais antiinterferon alfa e métodos para uso |
WO2008137838A2 (en) * | 2007-05-03 | 2008-11-13 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
KR20180090396A (ko) | 2008-01-18 | 2018-08-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법 |
BR122020023189B1 (pt) | 2008-02-08 | 2022-02-01 | Astrazeneca Ab | Uso de uma composição farmacêutica compreendendo um anticorpo específico para ifnar1 |
JP5766598B2 (ja) | 2008-05-07 | 2015-08-19 | アーゴス セラピューティクス インコーポレイテッド | ヒトインターフェロン−αに対するヒト化抗体 |
CA2743590A1 (en) * | 2008-11-12 | 2010-05-20 | Yeda Research And Development Co. Ltd. | Diagnosis of multiple sclerosis |
CN101812119B (zh) * | 2009-02-25 | 2012-02-01 | 上海荣盛生物药业有限公司 | 与免疫抗体相结合的多肽及其应用 |
WO2012012694A2 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
KR20130041962A (ko) | 2010-07-23 | 2013-04-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 식작용 세포를 사용하여 질환 또는 상태를 검출하는 방법 |
US20130203624A1 (en) | 2010-07-23 | 2013-08-08 | President And Fellows Of Harvard College | Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions |
AU2010365277B2 (en) | 2010-12-06 | 2017-01-05 | Thd S.P.A. | Method for the diagnosis of a carcinoma and uses thereof |
US9823246B2 (en) | 2011-12-28 | 2017-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescence enhancing plasmonic nanoscopic gold films and assays based thereon |
US9303247B2 (en) | 2012-02-10 | 2016-04-05 | Hakushinkouseikai Foundation | Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine |
NZ771629A (en) | 2013-03-09 | 2022-12-23 | Harry Stylli | Methods of detecting cancer |
US11585814B2 (en) | 2013-03-09 | 2023-02-21 | Immunis.Ai, Inc. | Methods of detecting prostate cancer |
KR101536697B1 (ko) * | 2013-11-29 | 2015-07-14 | 아주대학교산학협력단 | 베체트병 진단용 조성물 |
MA40636A (fr) | 2014-09-11 | 2015-09-11 | Colleen Kelly | Procédés pour détecter le cancer de la prostate |
CN107110851B (zh) | 2014-11-05 | 2019-10-22 | 纳迈达斯生物科技中心 | 用于增强成像的金属复合物 |
KR20200039778A (ko) | 2017-08-22 | 2020-04-16 | 사나바이오, 엘엘씨 | 가용성 인터페론 수용체 및 그의 용도 |
BR112020016400A2 (pt) | 2018-02-14 | 2020-12-15 | Viela Bio, Inc. | Anticorpos para o ligante do receptor de tirosina cinase 3 similar ao sarcoma felino de mcdonough (fms) (flt3l) e suas utilizações para o tratamento de doenças autoimunes e inflamatórias |
WO2019204634A1 (en) * | 2018-04-20 | 2019-10-24 | Stc. Unm | Rap1-gtp, rac1-gtp and fms-like tyrosine kinase 3 ligand (flt3-l) as biomarkers for early detection of sepsis |
US20210215692A1 (en) * | 2018-06-11 | 2021-07-15 | University Of Washington | Compositions and methods for treating inflammatory diseases |
CN113238061B (zh) * | 2021-07-09 | 2021-10-01 | 中南大学湘雅医院 | 以cd180阴性b细胞指示重症肌无力病情的试剂盒及应用 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4423147A (en) | 1980-04-11 | 1983-12-27 | Secher David S | Monoclonal antibody to interferon-α |
NZ198445A (en) | 1980-09-25 | 1984-05-31 | Genentech Inc | Production of human fibroblast interferon by recombinant dna technology |
US4456748A (en) | 1981-02-23 | 1984-06-26 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4414150A (en) | 1980-11-10 | 1983-11-08 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4824432A (en) | 1981-03-24 | 1989-04-25 | S.V.S. Laboratories, Inc. | Method for treating AIDS and other immune deficiencies and immune disorders |
US4605394A (en) | 1982-12-03 | 1986-08-12 | Simon V. Skurkovich | Methods for the treatment of pathological conditions by removing interferon from the organism |
US4362155A (en) | 1981-03-24 | 1982-12-07 | Skurkovich Simon V | Method and apparatus for the treatment of autoimmune and allergic diseases |
DE3211263A1 (de) * | 1981-03-31 | 1983-01-27 | Otsuka Pharmaceutical Co. Ltd., Tokyo | Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung |
US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
US5582824A (en) | 1981-10-19 | 1996-12-10 | Genentech, Inc. | Recombinant DES-CYS-TYR-CYS human immune interferon |
AU561343B2 (en) * | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
US5096705A (en) * | 1981-10-19 | 1992-03-17 | Genentech, Inc. | Human immune interferon |
US5827694A (en) * | 1982-03-08 | 1998-10-27 | Genentech, Inc. | DNA encoding non-human animal interferons, vectors and hosts therefor, and recombinant production of IFN polypeptides |
US5831023A (en) | 1982-11-01 | 1998-11-03 | Genentech, Inc. | Recombinant animal interferon polypeptides |
US4534906A (en) * | 1982-11-01 | 1985-08-13 | Genentech, Inc. | Removal of impurities from human leukocyte interferon preparations |
JPS60500864A (ja) * | 1983-02-04 | 1985-06-06 | ワドリ、テクナラジズ、インコーパレイティド | 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ |
GB2148299B (en) * | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
US4855238A (en) | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
US5082658A (en) * | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
FR2560212B1 (fr) * | 1984-02-24 | 1989-12-29 | Unicet | Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps |
US4650674A (en) | 1984-07-05 | 1987-03-17 | Genentech, Inc. | Synergistic cytotoxic composition |
US5196323A (en) | 1985-04-27 | 1993-03-23 | Boehringer Ingelheim International Gmbh | Process for preparing and purifying alpha-interferon |
US4828830A (en) * | 1986-01-24 | 1989-05-09 | Genentech, Inc. | Method and composition for prophylaxis and treatment of viral infections |
JPS6330426A (ja) | 1986-07-25 | 1988-02-09 | Mitsubishi Chem Ind Ltd | 自己免疫性疾患治療薬 |
US4851219A (en) * | 1986-11-18 | 1989-07-25 | Genentech, Inc. | Method for the treatment of chronic myelogenous leukemia |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US4944941A (en) * | 1987-08-07 | 1990-07-31 | Genentech, Inc. | Methods and compositions for the treatment of lung conditions |
US5254678A (en) | 1987-12-15 | 1993-10-19 | Gene Shears Pty. Limited | Ribozymes |
AU2844889A (en) | 1988-01-22 | 1989-07-27 | Collagen Corporation | Method for suppressing the growth of normal and cancer cells |
CA1340323C (en) | 1988-09-20 | 1999-01-19 | Arnold E. Hampel | Rna catalyst for cleaving specific rna sequences |
US5168053A (en) * | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
US5889151A (en) * | 1989-10-20 | 1999-03-30 | Societe Leb-Tech | Purified human alpha interferon receptor |
US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
DE69131426T2 (de) * | 1991-04-17 | 2000-01-27 | Medisup Int Nv | Neue wasserlösliche polypeptide mit hoher affinität für alpha- und beta- interferone |
US5227158A (en) | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
ATE144149T1 (de) * | 1991-08-30 | 1996-11-15 | Genentech Inc | Therapeutisches verfahren zur behandlung von iddm |
US5248499A (en) * | 1991-10-07 | 1993-09-28 | Genentech, Inc. | Control of microbial infections in transplant patients |
EP0563487A1 (en) * | 1992-03-31 | 1993-10-06 | Laboratoire Europeen De Biotechnologie S.A. | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
US5821078A (en) * | 1992-09-03 | 1998-10-13 | Yeda Research And Development Co. Ltd. | Nucleic acid encoding interferon-α/β binding protein |
US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
NZ314644A (en) | 1993-05-24 | 2000-11-24 | Immunex Corp | Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue |
US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
US6630143B1 (en) | 1993-05-24 | 2003-10-07 | Immunex Corporation | Antibodies against flt3 ligand |
EP0725654A1 (en) * | 1993-09-17 | 1996-08-14 | Laboratoire Europeen De Biotechnologie S.A. | Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon |
US5959085A (en) * | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
US5780027A (en) * | 1995-07-14 | 1998-07-14 | Meiogen Biotechnology Corporation | Methods of treatment of down syndrome by interferon antagonists |
IL118096A0 (en) | 1996-05-01 | 1996-09-12 | Yeda Res & Dev | Antibodies against interferon alpha/beta receptor |
US6713609B1 (en) * | 1996-07-16 | 2004-03-30 | Genentech, Inc. | Monoclonal antibodies to type I interferon receptor |
US5859183A (en) * | 1997-02-13 | 1999-01-12 | The Rockefeller University | Altered telomere repeat binding factor |
US20030018174A1 (en) * | 1997-10-06 | 2003-01-23 | Genentech, Inc. | Monoclonal antibodies to IFNAR2 |
EP2058389B1 (en) | 1997-10-27 | 2016-05-18 | Rockefeller University | Defined dendritic cell maturation medium comprising TNF-alpha, IL-1beta, IL-6 |
WO1999029863A1 (en) * | 1997-12-08 | 1999-06-17 | Genentech, Inc. | Human interferon-epsilon: a type i interferon |
ZA9811070B (en) * | 1997-12-08 | 2000-07-03 | Genentech Inc | Type I interferons. |
US6291661B1 (en) * | 1998-07-02 | 2001-09-18 | Immunex Corporation | flt3-L mutants and method of use |
US6673908B1 (en) | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
JP2003521900A (ja) | 1999-12-30 | 2003-07-22 | ファイロジックス・エルエルシー | 前駆細胞保存因子、並びに関連する方法および産物 |
GB0001710D0 (en) * | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic treatment |
US6846486B1 (en) * | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
US6660523B2 (en) * | 2000-09-21 | 2003-12-09 | Schering Corporation | Dendritic cells; methods |
EP1351707B9 (en) * | 2001-01-09 | 2012-01-25 | Baylor Research Institute | Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
FR2822845B1 (fr) * | 2001-03-30 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques |
US6554512B2 (en) * | 2001-04-26 | 2003-04-29 | Zih Corp. | Printer for printing deformable flat supports and its loader |
AU2004233346B2 (en) | 2003-04-23 | 2008-03-06 | Medarex, Inc. | Humanized antibodies to interferon alpha receptor-1 (IFNAR-1) |
CN102344491B (zh) * | 2003-12-10 | 2015-03-11 | 梅达雷克斯有限责任公司 | 干扰素α抗体及其用途 |
NZ554065A (en) | 2004-10-07 | 2010-12-24 | Univ Zuerich | Use of an anti-interferon-alpha antibody for prevention and treatment of psoriasis |
-
2002
- 2002-01-08 EP EP02714705A patent/EP1351707B9/en not_active Revoked
- 2002-01-08 DE DE60239522T patent/DE60239522D1/de not_active Expired - Lifetime
- 2002-01-08 KR KR1020037009204A patent/KR100951409B1/ko active IP Right Grant
- 2002-01-08 AT AT02714705T patent/ATE502648T1/de active
- 2002-01-08 WO PCT/US2002/000343 patent/WO2002067760A2/en active IP Right Grant
- 2002-01-08 CA CA2433806A patent/CA2433806C/en not_active Expired - Lifetime
- 2002-01-08 US US10/466,023 patent/US7544357B2/en not_active Expired - Lifetime
- 2002-01-08 MX MXPA03006100A patent/MXPA03006100A/es active IP Right Grant
- 2002-01-08 JP JP2002567137A patent/JP4394350B2/ja not_active Expired - Fee Related
- 2002-01-08 AU AU2002246955A patent/AU2002246955B2/en not_active Expired
- 2002-01-08 US US10/042,644 patent/US20020160974A1/en not_active Abandoned
- 2002-01-08 BR BR0206364-6A patent/BR0206364A/pt not_active Application Discontinuation
- 2002-01-08 DK DK02714705.7T patent/DK1351707T3/da active
- 2002-01-08 CN CN200910160480A patent/CN101612402A/zh active Pending
- 2002-01-08 CN CNB028035569A patent/CN100536919C/zh not_active Expired - Lifetime
- 2002-01-08 ES ES02714705T patent/ES2363761T3/es not_active Expired - Lifetime
- 2002-01-08 EP EP10163628A patent/EP2236156A3/en not_active Withdrawn
-
2004
- 2004-04-14 HK HK04102607.7A patent/HK1061353A1/xx not_active IP Right Cessation
-
2009
- 2009-03-16 JP JP2009063336A patent/JP2009132736A/ja not_active Withdrawn
- 2009-05-04 US US12/435,267 patent/US20090263474A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2433806C (en) | 2011-03-15 |
US20020160974A1 (en) | 2002-10-31 |
EP1351707A4 (en) | 2004-12-15 |
MXPA03006100A (es) | 2005-02-14 |
US20090263474A1 (en) | 2009-10-22 |
WO2002067760A2 (en) | 2002-09-06 |
JP4394350B2 (ja) | 2010-01-06 |
ES2363761T3 (es) | 2011-08-16 |
US7544357B2 (en) | 2009-06-09 |
AU2002246955B2 (en) | 2007-03-22 |
CN100536919C (zh) | 2009-09-09 |
EP2236156A2 (en) | 2010-10-06 |
HK1061353A1 (en) | 2004-09-17 |
WO2002067760A3 (en) | 2003-03-13 |
EP2236156A3 (en) | 2011-01-05 |
CN101612402A (zh) | 2009-12-30 |
EP1351707A2 (en) | 2003-10-15 |
KR100951409B1 (ko) | 2010-04-07 |
EP1351707B1 (en) | 2011-03-23 |
DE60239522D1 (de) | 2011-05-05 |
JP2004519475A (ja) | 2004-07-02 |
CA2433806A1 (en) | 2002-09-06 |
CN1529617A (zh) | 2004-09-15 |
JP2009132736A (ja) | 2009-06-18 |
US20040067232A1 (en) | 2004-04-08 |
ATE502648T1 (de) | 2011-04-15 |
EP1351707B9 (en) | 2012-01-25 |
BR0206364A (pt) | 2005-08-16 |
KR20030070100A (ko) | 2003-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1351707T3 (da) | Fremgangsmåder til behandling af autoimmunsygdomme hos et individ og in vitro-diagnostiske analyser | |
DK1409544T3 (da) | Humane DR4-antistoffer og anvendelser deraf | |
DE69836630D1 (de) | Menschliche toll-ähnliche rezeptorproteine, zugehörige reagenzien und verfahren | |
DE60138829D1 (de) | Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker | |
AT500379A3 (de) | Tau-proteine | |
ATE378403T1 (de) | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern | |
ATE516304T1 (de) | Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden | |
DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
DE60331677D1 (de) | Kit zur untersuchung von menschlichem niedermolekulargewicht cd14 und antikörper | |
DK1181319T3 (da) | Kimære DR4-antistoffer og anvendelser deraf | |
DE602004016499D1 (de) | Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung | |
WO2003004045A3 (en) | Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors | |
DE60224200D1 (de) | Assayverfahren für alzheimer-krankheit | |
DK0946873T3 (da) | Fremgangsmåde til diagnose af allergisk bronkopulmonal aspergillose | |
DE69204157T2 (de) | Verfahren zur bestimmung von anti-rns-antikörpern. | |
DE60035267D1 (de) | Verfahren zur analyse der menge an intraabdominalem fettgewebe | |
DK1406927T3 (da) | Glycopeptider, fremstilling og anvendelse deraf til diagnosticering eller terapeutisk behandling af dissemineret sklerose | |
ATE375389T1 (de) | Verfahren zur diagnose, prognose und behandlung von glaukom und verwandten erkrankungen | |
DE60230988D1 (de) | Proteine in der diabetes-proteomanalyse | |
ATE275268T1 (de) | Verfahren zur diagnose von sjögren-syndrom | |
ATE329638T1 (de) | Vorrichtung, um in einem zielgebiet eines menschlichen oder tierischen körpers einen künstlichen isolierten kreislauf zu etablieren | |
PL400309A1 (pl) | Kwasy nukleinowe, proteiny oraz przeciwciala BTL-II | |
ATE393238T1 (de) | Il-4 rezeptor sequenzvarianten, die mit typ i diabetes assoziiert sind | |
ATE481498T1 (de) | Verfahren zur messung von neprilysinaktivität | |
SE0202608D0 (sv) | New sequences |